Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Ansofaxine hydrochloride extended-release tablets for major depressive disorder has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Ansofaxine hydrochloride extended-release tablets (Ansofaxine hydrochloride)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Major Depressive Disorder (MDD) | Phase 3 | Status: COMPLETED